Recent Quotes (30 days)

You have no recent quotes
chg | %

Resverlogix Corp.  

(Public, TSE:RVX)   Watch this stock  
Find more results for RVX
1.36
+0.05 (3.82%)
Nov 21 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.35 - 1.40
52 week 1.23 - 2.41
Open 1.39
Vol / Avg. 50,920.00/33,589.00
Mkt cap 156.59M
P/E     -
Div/yield     -
EPS -0.67
Shares 111.21M
Beta 0.81
Inst. own     -
Dec 12, 2017
Resverlogix Corp Annual Shareholders Meeting - 3:30PM EST - Add to calendar
  

Key stats and ratios

Q3 (Jul '17) 2017
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -602.93% -181.34%
Return on average equity - -
Employees 28 -
CDP Score - -

Address

300-4820 Richard Rd SW
CALGARY, AB T3E 6L1
Canada
+1-403-2549252 (Phone)
+1-403-2568495 (Fax)

Website links

Description

Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, dialysis, Alzheimer's disease, Fabry disease, other orphan diseases, and peripheral artery disease. Apabetalone is being studied in a Phase III trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

Officers and directors

Donald J. McCaffrey Chairman of the Board, President, Chief Executive Officer, Secretary
A. Brad Cann Chief Financial Officer
Jan O. Johansson M.D. Ph.D. Senior Vice President - Medical Affairs
Kenneth Lebioda Senior Vice President - Business & Corporate Development
Michael T. Sweeney M.D. Senior Vice President - Clinical Development
Norman Wong M.D. Chief Scientific Officer
Eldon R. Smith M.D. Lead Director
Age: 75
Norma K. Biln Director
Shawn Lu Director
Kelly B. McNeill Independent Director